07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

ItMSCs: Phase IIa data

Stemedica’s CardioCell LLC subsidiary reported top-line data from a single-blind, crossover, U.S. Phase IIa trial in 22 chronic heart failure patients with non-ischemic cardiomyopathy and LVEF <=40% showing that a single dose of 1.5 million...
07:00 , Aug 30, 2016 |  BC Extra  |  Clinical News

CardioCell reports Phase IIa heart failure data

Data presented at the European Society of Cardiology meeting in Rome showed that a single intravenous administration of ischemic-tolerant mesenchymal stem cells ( itMSCs ) from CardioCell LLC met the primary safety endpoint and several...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

ItMSCs: Phase IIa started

Stemedica’s CardioCell LLC subsidiary began a single-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate a single dose of 1.5 million cells/kg IV itMSCs in about 20 CHF patients with non-ischemic cardiomyopathy. The product is...
07:00 , Apr 7, 2014 |  BioCentury  |  Emerging Company Profile

Recardio: Cardiac regeneration

Recardio GmbH is developing a DPP-4 inhibitor in acute myocardial infarction to promote cardiac tissue regeneration and avoid subsequent heart failure. The compound could offer a less invasive alternative to stem cell transplantation procedures. Current...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Clinical News

ItMSCs: Phase IIa started

Stemedica's CardioCell LLC subsidiary began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate a single dose of IV itMSCs in about 50 patients with ST-segment elevation MI (STEMI). Stemedica Cell Technologies Inc. , San...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Clinical News

ItMSCs: Phase III started

Stemedica's CardioCell LLC subsidiary said Kazakhstan's National Scientific Medical Center began a Kazakhstani Phase III trial to evaluate IV itMSCs in about 120 patients with acute MI. Altaco XXI (Astana, Kazakhstan) has exclusive distribution rights...
07:00 , May 7, 2012 |  BC Week In Review  |  Clinical News

ItMSCs: Phase II data

A double-blind Phase II trial in 45 patients who experienced an acute MI and underwent reperfusion by stent showed that IV itMSCs given on day 7 improved LVEF by 11 points vs. placebo. Additionally, itMSCs...